TheraRadar
← Back
Data updated: Jun 28, 2026

REGCON HOLDINGS

Generics

REGCON HOLDINGS is a generic drug manufacturer focused on Cardiovascular, Neurology, Oncology.

1999
Since
42
Drugs
-
Trials
1
New Drugs (2yr)
Modality:

REGCON HOLDINGS's Key Drugs

REGCON HOLDINGS's core commercial portfolio centers on BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, spanning Cardiovascular and Neurology — its most strategically important drugs approved in the last 15 years.

REGCON HOLDINGS's Therapeutic Areas

REGCON HOLDINGS's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 35%
6 drugs
Neurology 29%
5 drugs
Oncology 12%
2 drugs
Gastroenterology 12%
2 drugs
Ophthalmology 12%
2 drugs

REGCON HOLDINGS's Top Competitors

REGCON HOLDINGS's closest competitors by therapeutic-area and drug-target overlap include Novartis, AbbVie, and Bayer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

REGCON HOLDINGS Pipeline Snapshot

Active clinical trials for REGCON HOLDINGS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • BRIMONIDINE TARTRATE AND TIMOLOL MALEATE leads revenue
  • Drug-level revenue analysis

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling